Clifutinib
Based on 1 Customer Validation
Clifutinib is an orally active and selective internal tandem duplication mutation of FMS-like tyrosine kinase 3 (FLT3-ITD) inhibitor with an IC50 value of 15.1 nM. Clifutinib exerts strong antiproliferative effects on FLT3-ITD acute myeloid leukemia (AML) cell lines (MV-4-11: IC50 = 1.5 nM; MOLM-13: IC50 = 1.4 nM). Clifutinib inhibits the activity of FLT3-ITD kinase and blocks the downstream RAS/MAPK, PI3K/AKT, and JAK/STAT5 signaling pathways of FLT3. Clifutinib induces apoptosis of acute myeloid leukemia (AML) cells with FLT3-ITD mutations. Clifutinib demonstrates significant antitumor efficacy in mice bearing MV-4-11 or MOLM-13 xenografts. Clifutinib is promising for research of relapsed/refractory FLT3-ITD-positive acute myeloid leukemia.
For research use only. We do not sell to patients.
- Purity : 99.59%
- CAS No.: 1862226-99-0
- Formula: C29H34N4O4
- Molecular Weight:502.60
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
In Vitro
Clifutinib (72 h) shows anti-proliferative activities against MV-4-11 AML cells and MOLM-13 cells, with IC50s of 1.5 nM and 1.4 nM, respectively[1].
Clifutinib (9e, 0.1-1000 nM, 72 h) exhibits potent antiproliferative activity against Ba/F3 cells expressing FLT3 mutant isoforms, with IC50 values of 0.9 nM (Ba/F3-FLT3-ITD), 4.1 nM (Ba/F3-FLT3-ITD-D835A), 5.8 nM (Ba/F3-FLT3-ITD-D835G), 47.6 nM (Ba/F3-FLT3-ITD-D835Y), 74.7 nM (Ba/F3-FLT3-ITD-D835 Del), 130.0 nM (Ba/F3-FLT3-ITD-D835V), 2.9 nM (Ba/F3-FLT3-ITD-D835N), 301.9 nM (Ba/F3-FLT3-ITD-D835I), 6.9 nM (Ba/F3-FLT3-ITD-N676D), 25.0 nM (Ba/F3-FLT3-ITD-G697R), 38.0 nM (Ba/F3-FLT3-ITD-Y842H), 21.8 nM (Ba/F3-FLT3-ITD-Y842R), 154.0 nM (Ba/F3-FLT3-ITD-F691L), 154.4 nM (Ba/F3-FLT3-ITD-F691I), 5.4 nM (Ba/F3-FLT3-D835Y), 10.9 nM (Ba/F3-FLT3-D835H), 37.4 nM (Ba/F3-FLT3-D835V), while showing no antiproliferative effect on parental Ba/F3 cells with IC50 > 1000 nM[1].
Clifutinib (1-10 μM, 72 h) exhibits significant antiproliferative activity only against FLT3-ITD+ leukemia cell lines MV-4-11 and MOLM-13 with IC50 values of 0.0015 μM and 0.0014 μM, respectively, while showing minimal or no antiproliferative effects on FLT3-ITD-negative cell lines (RS4;11, HL-60, MOLT-4, RPMI8226, K562, NCI-H226, PC-3, DU 145, SK-OV-3, OVCAR-3, MCF-7, SW-620, COLO205, Caki-1, U87MG, U251) with IC50 > 10 μM, and weak activity against NCI-H460, A2780, HCT116, 786-O cells with IC50 values of 7.8 μM, 7.2 μM, 8.5 μM, 3.4 μM, respectively[1].
Clifutinib (1-100 nM, 48-72 h) induces apoptosis in MV-4-11 cells in a dose-dependent manner[1].
Clifutinib (1-1000 nM, 2 h) inhibits the phosphorylation of FLT3, ERK, AKT, and STAT5 in MV-4-11 cells in a dose-dependent manner without affecting total protein levels[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MV-4-11 cells
-
Concentration:1, 3, 10, 30, 100 nM
-
Incubation Time:48, 72 h
-
Result:Induced apoptosis in MV-4-11 cells in a dose-dependent manner.
-
Cell Line:MV-4-11 cells
-
Concentration:1, 3, 10, 30, 300, 1000 nM
-
Incubation Time:2 h
-
Result:Inhibited the phosphorylation of FLT3, ERK, AKT, and STAT5 in MV-4-11 cells in a dose-dependent manner without affecting total protein levels.
Parmacokinetics
| Species | Dose | Route | Tmax | Cmax | AUClast | T1/2 | CL | Vss | F |
|---|---|---|---|---|---|---|---|---|---|
| Dog[1] | 1 mg/kg | i.v. | 0.083 h | 633 ng/mL | 1290 ng·h/mL | 6.28 h | 11.3 mL/min/kg | 5.08 L/kg | / |
| Dog[1] | 5 mg/kg | p.o. | 1.67 h | 520 ng/mL | 4870 ng·h/mL | 7.41 h | / | / | 71.91 % |
| Mice[1] | 10 mg/kg | p.o. | 0.5 h | 1660 ng/mL | 4380 ng·h/mL | 1.73 h | / | / | 50.3 % |
| Mice[1] | 2 mg/kg | i.v. | 0.083 h | 1820 ng/mL | 1.740 ng·h/mL | 1.17 h | 18.9 mL/min/kg | 1.36 L/kg | / |
| Monkey[1] | 1 mg/kg | i.v. | 0.083 h | 4720 ng/mL | 10100 ng·h/mL | 13.1 h | 1.35 mL/min/kg | 0.996 L/kg | / |
| Monkey[1] | 5 mg/kg | p.o. | 4 h | 1410 ng/mL | 10800 ng·h/mL | 8.94 h | / | / | 20.05 % |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Human tumor xenografts were established by subcutaneous inoculation of mice (Female NOD/SCID or Balb/c nudemice (5-6 weeks old)) with MV-4-11 or MOLM-13 cells[1]
-
Dosage:0.5, 1.5, 4.5, 20 mg/kg
-
Administration:p.o., once daily, 8, 10 or 21 days
-
Result:Achieved tumor growth inhibition.
Showed no significant changes in body weight.
Achieved complete inhibition of FLT3 and STAT5 phosphorylation in MV-4-11 xenografts .
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1862226-99-0
-
Appearance Solid
-
Molecular Weight 502.60
-
Formula C29H34N4O4
-
Color White to off-white
-
SMILES
O=C(NC1=NOC(C(C)(C)C)=C1)NC2=CC=C(C#CC3=CC=C(OCCCN4CCOCC4)C=C3)C=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 25 mg/mL (49.74 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9897 mL | 9.9483 mL | 19.8965 mL | 49.7413 mL |
| 5 mM | 0.3979 mL | 1.9897 mL | 3.9793 mL | 9.9483 mL | |
| 10 mM | 0.1990 mL | 0.9948 mL | 1.9897 mL | 4.9741 mL | |
| 15 mM | 0.1326 mL | 0.6632 mL | 1.3264 mL | 3.3161 mL | |
| 20 mM | 0.0995 mL | 0.4974 mL | 0.9948 mL | 2.4871 mL | |
| 25 mM | 0.0796 mL | 0.3979 mL | 0.7959 mL | 1.9897 mL | |
| 30 mM | 0.0663 mL | 0.3316 mL | 0.6632 mL | 1.6580 mL | |
| 40 mM | 0.0497 mL | 0.2487 mL | 0.4974 mL | 1.2435 mL |